BHCM
PTCT icon

Brevan Howard Capital Management’s PTC Therapeutics PTCT Stock Holding History

Brevan Howard Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,473
Closed -$416K – 2421
2025
Q4 		$416K Sell
5,473
-8,013
-59% -$582K ﹤0.01% 1200
2025
Q3 		$828K Sell
13,486
-36,901
-73% -$1.92M ﹤0.01% 990
2025
Q2 		$2.46M Buy
+50,387
New +$2.39M 0.01% 658
2025
Q1 		– Sell
-12,197
Closed -$551K – 1396
2024
Q4 		$551K Buy
+12,197
New +$522K ﹤0.01% 587
2024
Q3 		– Sell
-18,665
Closed -$571K – 1375
2024
Q2 		$571K Buy
+18,665
New +$605K 0.01% 555

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Brevan Howard Capital Management's PTCT Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 5,473 shares — an estimated $416K sold.

Brevan Howard Capital Management first reported a position in PTCT in Q2 2024 and held it in 5 quarters. The position peaked at $2.46M in Q2 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 5,473 PTC Therapeutics shares in Q1 2026, an estimated $416K.
  • Brevan Howard Capital Management first reported a position in PTC Therapeutics in Q2 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's PTC Therapeutics position peaked at $2.46M in Q2 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.